Aurobindo Pharma stock erased early gains and fell in today’s trade as
the USFDA
issued a ‘Form 483’ with 9 observations to its subsidiary, AuroLife
Pharma’s manufacturing facility in the US.
Aurobindo Pharma stock erased early gains and fell in today’s trade as
the USFDA
issued a ‘Form 483’ with 9 observations to its subsidiary, AuroLife
Pharma’s manufacturing facility in the US.